Catherine Rea, Thomas York, Ulrike Lorch, Kate Khair, Luke Pembroke, Jigar Amin

New insights from a prospective study on Glanzmann thrombasthenia (GT) have been published in Blood (2023). Led by Catherine Rea, Thomas York, Ulrike Lorch, and their team, this observational study delves into the bleeding patterns and impacts on quality of life (QOL) in 30 GT patients over 3 months. Using a custom-designed electronic bleed diary, the study reveals the high frequency of bleeds and their substantial socioeconomic impacts. Results detail bleed rates, anatomical locations, associated symptoms, and the burden on daily activities. The findings underscore the urgent need for improved treatments to reduce bleed frequency and enhance QOL for GT patients. This study establishes a direct correlation between bleed events and their profound effects on patients' lives, advocating for advancements in GT care.

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event